Optimal Pre-dilatation Treatment before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis. The OPTIMIS trial

Kirstine Nørregaard Hansen MD[1,2], Jens Trøan MD[1], Akiko Maehara MD[3], Manijeh Noori MD[1,2], Mikkel Hougaard MD PhD[1], Julia Ellert-Gregersen MD PhD[1], Karsten Tange Veien MD[1], Anders Junker MD PhD[1], Henrik Steen Hansen MD[1,2], Jens Flensted Lassen MD PhD[1,2], Lisette Okkels Jensen MD DMSci PhD[1,2]

[1]Department of Cardiology, Odense University Hospital, Odense, Denmark

[2]University of Southern Denmark, Odense, Denmark

[3]Cardiovascular Research Foundation, New York Presbyterian Hospital, New York, USA

Short title: Bioresorbable scaffolds and lesion preparation

Word count: 4,805

Correspondence to:
Kirstine Nørregaard Hansen MD
Odense University Hospital
Department of Cardiology
Sdr. Boulevard 29
5000 Odense C
Denmark
E-mail: kirstinenoerregaard@live.dk
Phone: +45 6541 2690

Abstract

Introduction: Bioresorbable scaffolds (BRS) have been developed to overcome limitations related to late stent failures of drug-eluting-stents, but previous studies have observed lumen reduction over time after implantation of BRS. The aim of the study was to investigate if lesion preparation with a scoring balloon compared to a standard non-compliant balloon minimizes lumen reduction after implantation of a Magmaris BRS (MgBRS) assessed with optical coherence tomography (OCT) and intravascular ultrasound (IVUS).

Method: Eighty-two patients with stable angina pectoris were included and randomized in a ratio 1:1 to lesion preparation with either a scoring balloon or a standard non-compliant balloon prior to implantation of a MgBRS. The primary endpoint was minimal lumen area (MLA) 6 months after MgBRS implantation.

Results: Following MgBRS implantation, MLA (6.4 ± 1.6 mm^2 vs. 6.3 ± 1.5 mm^2, p=0.65), mean scaffold area (7.8 ± 1.5 mm^2 vs. 7.5 ± 1.7 mm^2, p=0.37), and mean lumen area (8.0 ± 1.6 mm^2 vs. 7.7 ± 2.1 mm^2, p=0.41) did not differ significantly in patients where the lesions were prepared with scoring vs. standard non-compliant balloon respectively. Six-month angiographic follow-up with OCT and IVUS was available in seventy-four patients. The primary endpoint, 6-months MLA, was significantly larger in lesions prepared with a scoring balloon compared to a standard non-compliant balloon (4.7 ± 1.4 mm^2 vs. 3.9 ± 1.9 mm^2, p=0.04), whereas mean lumen area (7.2 ± 1.4 mm^3 vs. 6.8 ± 2.2, p=0.35) did not differ significantly. IVUS findings showed no difference in mean vessel area at the lesion site from baseline to follow-up in the scoring balloon group (16.8 ± 2.9 mm^2 vs. 17.0 ± 3.6 mm^2, p=0.62), whereas mean vessel area (17.1 ± 4.4 mm^2 vs. 15.7 ± 4.9 mm^2, p<0.001) was smaller in lesions prepared with a standard non-compliant balloon due to negative remodeling.

Conclusion: Lesion preparation with a scoring balloon prior to implantation of a MgBRS resulted in significantly larger MLA after 6 months due to less negative remodeling compared to lesion preparation with a standard non-compliant balloon.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04666584.

Clinical perspectives:

What is new?

- Intense lesion preparation with a scoring balloon prior to implantation of a magnesium-based Magmaris bioresorbable scaffold results in less lumen reduction and malapposition after 6 month compared to conventional lesion preparation with a non-compliant balloon in patients with stable angina.
- Negative remodeling was seen in lesions treated with conventional lesion preparation, whereas optimal lesion preparation with a scoring balloon caused in stable remodeling.

What are the Clinical Implications?

- Lesions preparation with a scoring balloon is safe and ensures better vascular healing and vessel dynamics after implantation of a magnesium-based Magmaris bioresorbable scaffold.
- Optimal lesion preparation should be considered before implantation of magnesium-based Magmaris bioresorbable scaffold.

Non-standard Abbreviations and Acronyms	
BRS	Bioresorbable scaffold
DAPT	Dual antiplatelet therapy
DES	Drug-eluting stents
EEM	External elastic membrane
IVUS	Intravascular ultrasound
MLA	Minimal lumen area
MgBRS	Magnesium-based Magmaris bioresorbable scaffold
NOAC	Novel oral anticoagulant
OCT	Optical coherence tomography
OPTIMIS	Optimal Pre-dilatation Treatment before Implantation of a Magmaris bioresorbable scaffold In coronary artery Stenosis
PCI	Percutaneous coronary intervention

62

Introduction

Bioresorbable scaffolds (BRS) were developed to provide temporary vessel support during the early phases of coronary vessel healing, leaving the artery stent-free after degradation as an alternative to drug-eluting stents (DES) during percutaneous coronary intervention (PCI)[1, 2]. The potential advantages of BRS were restored vasomotion and potential reduction in late stent failures. The Absorb everolimus-eluting BRS (Abbott Vascular, Abbott Park, IL, USA) showed increased risk of scaffold thrombosis and vessel shrinkage over time[3] with significant minimal lumen area (MLA) reduction after 6 months assessed with optical coherence tomography (OCT)[4]. It is hypothesized that the mechanism behind lumen reduction is based on decreased radial strength in BRS compared with bare-metal stents and risk of recoil and scaffold dismantling[5]. The construction of BRS continued to develop, and different types are now available on the market. The magnesium-based BRS (Magmaris, Biotronik, Bülach, Switzerland) (MgBRS) was later introduced with improved radial strength, stronger backbone, change in drug-polymer coating and showed better efficacy compared to the first BRSs[6-9]. Head-to-head comparison between newer generation DES and the MgBRS is limited, but the anti-restenotic efficacy has not yet solved the scaffold failure[5, 10]. Optimal lesion preparation prior to implantation of a MgBRS appeared to facilitate optimal scaffold sizing and better expansion post-procedure in complex lesions[11], but the effect of aggressive pre-dilation on vessel and lumen changes over time is uncertain. Peri-procedural intravascular imaging is recommended during implantation of a MgBRS due to lack of a radiolucent backbone. OCT is ideal to assess lumen contours[12], whereas intravascular ultrasound (IVUS) provides information on the vessel wall and vessel remodeling over time[13, 14]. The aim of this study was to assess whether a more aggressive lesion preparation with a scoring balloon compared to a standard non-compliant balloon prior to implantation of a MgBRS resulted in less lumen reduction MLA after 6 months.

Methods

Study design

The OPTIMIS (Optimal pre-dilatation Treatment before Implantation of a Magmaris bioresorbable scaffold In coronary artery Stenosis) study was a prospective, randomized-controlled trial conducted at Odense University Hospital in Denmark from December 2020 to September 2023. The study compared lesion preparation with a scoring balloon to a standard non-compliant balloon, prior to implantation of a MgBRS and the effect on lumen dimension in the scaffold treated segment after 6 months. The patients were randomized to the two pre-dilatation methods in a ratio 1:1. The primary hypothesis of the OPTIMIS-study was that intense lesion preparation with a scoring balloon prior to implantation for a MgBRS would result in a larger MLA after 6-month follow-up, compared to standard pre-dilatation with a non-compliant balloon. A detailed description of the study design has previously been published[15].

The study was approved by the Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20200114) and Danish Data Agency (Journal no.: 20/49900), the trial was registered at ClinicalTrials.gov (NCT04666584).

Patient population

Eighty-two patients with stable angina pectoris referred to PCI were enrolled in the study, if they met the inclusion criteria. Patients were eligible if; 1) age was between 18 and 80 years, 2) if they had stable angina pectoris, 3) the target lesion was in a native coronary artery, 4) vessel was suitable for treatment with MgBRS complying with the scaffolds recommended limitations of coronary artery diameter between ≥ 2.75 mm and ≤ 4.0 mm measured with OCT or IVUS. Exclusion criteria were 1) patients participating in other randomized stent studies, 2) expected survival < 1 year, 3) allergy to aspirin, ticagrelor, clopidogrel or prasugrel, 4) allergy to sirolimus, 4) ostial lesions (cannot be cleared with flush by OCT), 5) serum creatinine > 150 µg/L (due to the required amount

of contrast by OCT), 6) vastly calcified (evaluated with OCT defined as an arc > 180º, calcium thickness > 0.5 mm and calcium length of > 5 mm), 7) tortuous coronary arteries where the PCI-operator estimated that the introduction of an OCT-catheter would not be possible or would be associated with increased risk, and/or, 8) lesion length > 40 mm. All patients were screened for protocol inclusion and exclusion criteria before enrolment. Patients underwent clinical and invasive imaging follow-up with OCT and IVUS at 6 months.

Antithrombotic therapy

Patients were treated with aspirin 75 mg /day prior to the PCI procedure. On the day for the PCI, they received a loading dose of 600 mg clopidogrel. Patients were prescribed dual antiplatelet therapy (DAPT) with aspirin 75 mg /day and clopidogrel 75 mg/day for 6 months followed by lifelong monotherapy with 75 mg of aspirin. Patients in Warfarin or novel oral anticoagulant (NOAC) were loaded with 600 mg of clopidogrel. If patients had been admitted and treated for an acute myocardial infraction within the last 12 months, patients kept their previously prescript antithrombotic medication.

Devices

The metallic-based MgBRS contains a magnesium alloy with a bioresobable poly-L-lactide acid polymer coated with sirolimus as eluting drug released completely after 100 days. The strut thickness is 150 µm. The MgBRS is completely absorbed after 1 year[16]. The scaffold sizes were available in a diameter of 3.0 mm and 3.5 mm, and lengths of 15, 20, and 25 mm.

The scoring balloon (ScoreFlex, OrbusNeich) catheter is a short mono-rail type balloon catheter. It provides forced dilatation with a dual-wire semi-compliant balloon system which facilitates local, safe and controlled plaque modification at lower resolution pressure.

Procedure strategy

The coronary stenosis was identified by the PCI operator's interpretation of the angiography and was treated with a MgBRS in all patients. Patients received a dose of heparin (70 UI/kg) prior to the procedure. At the discretion of the operator, pre-dilatation with a 2.0 mm balloon was allowed. Pre-interventional imaging with OCT and IVUS was performed. The scaffold sizing was based on the external elastic membrane (EEM) diameters of the proximal and distal reference segments. If the EEM was visible in >180º of the cross sectional area, the smaller EEM diameter rounded down to the nearest 0.5 mm was used to determine scaffold diameter. If the EEM was visible in <180º, the scaffold diameter was based on the lumen diameter[17]. Patients were allocated 1:1 to either lesion preparation with 1) a scoring balloon, or 2) a standard non-compliant balloon. The lesion was pre-dilated in a 1:1 balloon:artery ratio. Up-scaling to a 0.5 mm larger balloon was allowed, if the pre-dilatation goal was not achieved, as long as the balloon type corresponded to the randomization arm. The pre-dilatation goal was an angiographic residual stenosis of less than 20%. The lesion was then treated with implantation of a MgBRS, and inflation pressure was maintained for 30 seconds during implantation. Mandatory post-dilatation was performed with a non-compliant balloon with the same size or maximally 0.5 mm larger than the implanted scaffold. Lastly, intravascular imaging with OCT and IVUS of the scaffold treated segment was performed and controlled by the PCI-operator and an on-site OCT-analyst. Optimization (if any) was performed at the operators' discretion. Additional intervention was allowed if there was 1) major under-expansion (minimal scaffold area (MSA) < 4.5 mm^2), 2) major malapposition (defined as strut > 0.3 mm from the lumen wall for > 3 mm), 3) presence of significant edge dissection, or 4) residual stenosis <5 mm proximal or distal to the scaffold (causing MLA < 4 mm^2). Repeated OCT and IVUS of the final result were

159 then performed. Blinding of the patient, PCI-operator or investigator to pre-dilatation technique was
160 not possible during the index procedure.
161
162 *Intravascular imaging acquisition*
163 OCT and IVUS were performed at baseline and after 6-month of follow-up. The imaging
164 procedures were preceded by administration of 200 µg of intracoronary nitroglycerin. OCT was
165 performed with frequency-domain OPTIS OCT system (Illumien OCT system; Abbott Vascular,
166 Santa Clara, CA, USA) using the Dragonfly^{TM} Imaging catheter. The catheter was positioned 10
167 mm distally to the lesion or scaffold-treated segment, and the coronary artery was then flushed with
168 15 ml contrast injection to clear the artery for blood during automated pullback at a rate of 20 mm/s
169 over a distance of 75 mm. The IVUS system (Boston Scientific, Marlborough, MA, USA) used a
170 40MHz OptiCross 2.6 Fr catheter placed 10 mm distally to the lesion or scaffold-treated segment.
171 Motorized IVUS pullbacks were performed with a pullback speed of 0.5 mm/sec after intracoronary
172 bolus of 200 µg nitroglycerine.
173
174 *Intravascular imaging analysis*
175 The intravascular imaging pullbacks were analyzed by two independent analysists who were both
176 blinded to the pre-dilatation technique during analysis. The baseline IVUS and OCT pullbacks were
177 matched with the follow-up images using anatomical landmarks. OCT offline software (Offline
178 Review Workstation; Abbott Vascular) was used for quantitative OCT analysis, and the
179 commercially available program for computerized IVUS-analysis Echoplaque (INDEC Systems,
180 Inc., Santa Clara, CA, USA) was used for IVUS-analysis. The scaffold-treated segment was
181 analyzed for every mm. Lumen dimensions at baseline and follow-up were measured: MLA, mean
182 lumen area, lumen volume, and difference in MLA (follow-up MLA – baseline MLA). Quantitative

analysis of scaffold was done using IVUS, because IVUS showed better detection of scaffold remnants than OCT. Scaffold dimensions at baseline were measured: MSA, mean scaffold area, minimum scaffold diameter, and scaffold volume. Scaffold malapposition was defined to be present when the distance between the abluminal surface of the strut and the luminal surface of the vessel wall exceeded the struts thickness of 150 µm. Major malapposition was defined as struts > 0.3 mm from the lumen wall for >3 mm in length[18], and the remaining were classified as minor. At baseline, malapposition area, distance, and volume were analyzed. At follow-up, visible struts or strut remnants were categorized as malapposed when the abluminal border of the strut/remnant was separated from the lumen surface by a visible space exceeding 150 µm. The malapposition observations was matched from baseline to follow-up and divided into resolved, persistent, or late acquired malapposition. If a scaffold contained both resolved and persistent malapposition at follow-up, it was summarized as persistent. To evaluate the effect of pre-dilatation method on remodeling in the specific lesion site, IVUS was used to identify the pre-procedure MLA in lesion. The lesion site was defined as 5 mm proximally and distally to MLA. The corresponding 10 mm segment was identified in IVUS pullback post-procedure and at 6-month follow-up using anatomical landmarks such as side branches, calcified plaques and scaffold edges. Remodeling was defined as changes in mean EEM area in the lesion site and deemed significant if the mean EEM area changed more than 0.5 mm^2. Enlargement was defined as positive remodeling, and reduction in mean EEM area was defined as negative remodeling. Quantitative IVUS analysis included measurements of EEM, peri-scaffold plaque (EEM area – scaffold area), and total plaque area (EEM area – lumen area).

Statistical analysis

Categorical data was presented as numbers and frequencies and compared using chi-square test or Fisher's exact statistics. Continuous data was presented as mean ± SD and compared using Student's t-test. Paired t-test was used for comparison from baseline to follow-up. If the distribution were skewed, a non-parametric test was performed, and median with interquartile range (IQR) was stated.

All tests were two-tailed, and a p-value <0.05 was considered statistically significant. STATA version 18.0 (StataCorp, Collage Station, TX, USA) was used for the statistical analysis. Inter-observer variability for imaging analysis was tested for consistency of agreement using an intraclass correlation coefficient (ICC) was calculated for MLA at follow-up and for malapposition area at baseline and follow-up. The Pearson correlation coefficient was used to evaluate the direction and strength of the linear relation between two parameters.

The estimated sample size was based on data from the HONEST study[19]. The reduction of MLA from 6.99 mm^2 to 5.01 mm^2 (27%) 6 months after implantation of the Magmaris BVS, represented the expected reference group. Optimal lesion preparation with pre-dilatation with a scoring balloon is estimated to minimize MLA reduction from 6.99 mm^2 to 6.22 mm^2 (11%). A power calculation is conducted using the expected MLA after 6 months (6.22 mm^2 for the scoring balloon and 5.01 mm^2 for the standard non-compliant balloon). Inclusion of 35 patients in each group is necessary to reach statistical significance in case of 2-tailed significance level of 0.05 and power of 80 %. Loss to follow-up and poor image quality finalize an expected drop-out rate of 15 %, thereby requiring 82 patients in total.

Endpoints

The primary endpoint was MLA in the scaffold-treated segment pre-dilated with a scoring balloon versus standard non-compliant balloon 6-month after implantation of a MgBRS assessed with OCT.

Secondary endpoints were differences between treatment groups in: 1) change in MLA, and 2) percentage and size of incomplete scaffold apposition at baseline and follow-up.

Results

A flowchart of enrolled patients is provided in Figure 1.

In total, 82 patients were enrolled in the study. Follow-up images were not available in 8 patients due to following reasons. One patient randomized to standard non-compliant balloon pre-dilatation was excluded due to vessel dissection that could not be covered by a MgBRS scaffold. Two patients were excluded, one in the scoring balloon group and one in the standard non-compliant balloon group, due to scaffold failure where the MgBRS was lost in the coronary artery proximally to the study lesion. In all three cases, patients were treated with a DES. Five patients had unavailable follow-up images: Two patients withdrew consents (one in the scoring balloon group and one standard non-compliant balloon group), one patient died within the 6-month angiographic follow-up (standard non-compliant balloon group), one patient had a subacute scaffold thrombosis 5 days after implantation (standard non-compliant balloon group), and one patient was postponed due to nurses' strike (standard non-compliant balloon group).

Clinical and procedural characteristics

Baseline clinical and procedural characteristics are presented in Table 1 and Table 2.

The treatment groups were well matched without any significant differences in baseline characteristics. Also, there were no significant differences in procedural characteristics, except for balloon length which was significantly shorter in the scoring balloon group (only available in 10 and 15 mm) (13.1 ± 2.5 mm vs. 15.5 ± 3.3 mm, $p < 0.001$) compared to the standard non-compliant balloon group.

Optical coherence tomography findings

Post-procedure and 6-month follow-up OCT findings are presented in Table 3. Inter-observer variability for MLA at follow-up was: ICC=0.996 (95% confidence interval (CI): 0.999-1.00, p<0.001), for total malapposition area at baseline: ICC=0.949 (95% CI: 0.77-0.99, p< 0.001), and for total malapposition at follow-up: ICC=0.874 (95% CI: 0.50-0.97, p=0.001).

Lumen dimensions

At baseline, there was no significant difference in MLA, mean LA, or lumen volume between the two treatment groups assessed with OCT. At 6-month follow-up, MLA (the primary endpoint) in the scaffold-treated segment was significantly larger in the patients allocated to pre-dilatation with a scoring balloon, compared to a standard non-compliant balloon (4.71 mm^2 ± 1.35 vs. 3.91 mm^2 ± 1.86, p = 0.04). There was no significant difference between the two groups in mean LA, or lumen volume at 6-month follow-up. There was a relative reduction in MLA of -24.8% for the scoring balloon group compared to -38.3% in the standard non-compliant balloon group, p=0.009. Representative cases of lumen reduction from baseline to follow-up are shown in Figure 2.

Scaffold measurements and malapposition

At baseline, scaffold parameters, such as scaffold length, mean scaffold area, minimal scaffold area, and total scaffold volume were similar in the two groups. Total number of analyzable struts were similar at baseline between the two groups (199.9 ± 70.5 in the scoring balloon group and 210.7 ± 60.0 in the standard non-compliant balloon group, p=0.46). At follow-up, the total number of analyzable struts were reduced to 70.8 ± 35.1 in the scoring balloon group and 85.1 ± 32.1 in the standard non-compliant balloon group (p=0.07).

At baseline, half of the scaffolds in both groups had minor malapposition. There were no major malappositions in any of the groups. Percentage of malapposed struts was small in both groups and significantly lower in the scoring balloon group with 1.5 % compared to 4.6 % in the standard non-compliant balloon group (p=0.02). At baseline, malapposition volume tended to be smaller in the scoring balloon group (0.38 mm^2 [0.15 ; 0.95]) compared to the standard non-compliant balloon group [1.07 mm^2 0.48 ; 2.27], but there was no significant difference (p= 0.09).

At 6-month follow-up, 15.4% of the lesions treated with the scoring balloon had minor malappositions, whereas 42.9% in the standard balloon group had minor malappositions (p=0.009). There significantly smaller total malapposition volume (0.0 [0.0 ; 0.0] vs. 0.21 [0.0 ; 0.59], p=0.009) and percentage of malapposed struts (0.0 [0.0 ; 0.0] vs. 1.62 [0.0 ; 3.49], p=0.004) in the scoring group compared to the standard non-compliant balloon group at 6-month follow-up. Type of malapposition did not differ between groups. Malappositions were resolved in 31.4 % of the scaffolds in the scoring balloon group, compared to 48.6% in the standard non-compliant balloon group. In the scoring balloon group, 5% had persistent malapposition vs. 20% in the standard balloon group. Late acquired malapposition was seen in 15.4% in the scoring balloon group compared to 22.9% in the standard non-compliant balloon group, and often positioned at scaffold edge and in relation to calcified plaque. Malapposition types are presented in Figure 3.
At 6-month follow-up, no scaffold area and volume were drawn since most of the struts were absorbed. OCT images of scaffold degradation are shown in Figure 2. The total number of struts were similar in the two groups, but there were significantly less struts per cross section in the scoring balloon group compared to standard non-compliant balloon group after 6 months.

Intravascular ultrasound findings

Post-procedure and 6-month follow-up IVUS findings are presented in Table 3 and Table 4 and Supplementary table 1.

Vessel dimensions

There was no difference in vessel measurements between the two groups at baseline or at 6-month follow-up (Table 3). The paired analysis of mean area in the 10 mm lesion site and corresponding segment post-procedure and at 6-month follow-up are presented in Table 4. There was no significant difference in mean lumen area from post-procedure to 6-month follow-up in the scoring balloon group (8.5 ± 1.4 mm^2 vs. 8.1 ± 1.8 mm^2, p=0.08), whereas a significant decrease in lumen area was found in the standard non-compliant balloon group (8.2 ± 1.7 mm^2 vs. 7.4 ± 2.6 mm^2, p=0.009). Vessel area in the 10 mm segment corresponding to the lesion site did not change in the scoring balloon group from baseline to 6-month follow-up (16.8 ± 2.9 mm^2 vs. 17.0 ± 3.6 mm^2, p=0.62), but was significantly decreased (17.1 ± 4.4 mm^2 vs. 15.7 ± 4.9 mm^2, $p < 0.001$) in the standard non-compliant balloon group indicating negative remodeling.

Pattern of remodeling

Figure 4 shows the relationship between relative change in lumen area and relative change in vessel area (A), and relative change in lumen area and relative change in plaque area (B). There was a significant positive correlation between relative change in lumen area and relative change in vessel area at the 10 mm lesion site (r=0.72, 95% CI: 0.58-0.81, p<0.001), but there was no correlation between relative change in lumen area and relative change in plaque area (r=-0.02, 95% CI: -0.25-0.21, p=0.88).

Clinical 6-month follow-up

In patients allocated to pre-dilatation with a scoring balloon prior to implantation of the MgBRS one patient had a target vessel revascularization not related to the scaffold-treated segment. There were no events observed corresponding to the scaffold-treated segment in the scoring balloon group. In patients treated with the standard balloon prior to implantation of the MgBRS following events were observed: one patient admitted with STEMI and subacute scaffold thrombosis 5 days after index procedure. This patient was only treated with aspirin for 4 days followed by monotherapy with clopidogrel as the patient also received NOAC; one patient died due to an intracranial hemorrhage 92 days after index procedure.

Discussion

In summary, we found that MLA assessed with OCT was significantly larger in the scoring balloon group compared to the standard non-compliant balloon group 6 month after implantation of the MgBRS. In both groups, MLA decreased from baseline to 6-month follow-up, but less MLA reduction was seen in the scoring balloon group compared to the standard non-compliant balloon group. At the lesion site, there was no change in remodeling from baseline to follow-up in the scoring balloon group, whereas negative remodeling was observed in lesions prepared with the standard non-compliant balloon. In the lesions pre-dilated with a scoring balloon, there was significantly less malapposition at follow-up compared to the standard non-compliant balloon group.

The magnesium-based BRS was first evaluated in the DREAM 1G study[20], where a significant decrease in MLA was observed within the first 6 months (7.9 mm^2 ± 1.2 vs. 5.7 mm^2 ± 1.0) after implantation assessed with OCT. The second generation magnesium-based BRS, MgBRS, had higher flexibility and higher radial force, than the first generation magnesium-based BRS[21].

Previous studies have investigated the vascular healing after 6 months of the magnesium-based BRS with both IVUS and OCT, but significant lumen decrease continued to occur[6, 19, 22, 23]. Assessed with OCT, malapposition, neointimal hyperplasia and strut coverage were near impossible to detect at follow-up, because the strut remnants had lost their metallic stent-like appearance during the absorption process. Interestingly, the BIOSOLVE-II study (BIOtroniks – Safety and performance in de nOvo Lesion of natiVE coronary arteries with Magmaris) reported measurable scaffold observation, such as mean and minimum scaffold area and incomplete strut apposition as visible with IVUS, but not with OCT at 6-month follow-up[22]. The same pattern applied to our findings, where scaffold area detection was not possible with OCT, but analyzable with IVUS at 6-month follow-up. The BIOSOLVE-II trial[22] measured smaller lumen and scaffold areas assessed with IVUS compared to OCT, which was unlike our findings with smaller lumen and scaffold measurements evaluated with OCT compared to IVUS. IVUS is often reported to overestimate lumen area compared to OCT[17], which may explain why no difference was found between the two groups when using IVUS in lumen or scaffold measurements.

A third generation magnesium-based BRS (DREAMS-3G) has been developed with larger size range, thinner struts (99/117/147 µm vs. 150 µm), and increased radial strength[24] compared to the MgBRS used in our study. An absolute reduction in MLA was -2.4 mm^2 (from 7.2 mm^2 to 4.8 mm^2 at 6-month follow-up) for the DREAMS-3G, which was comparable to our results in the standard non-compliant balloon group with an absolute reduction of -2.3 mm^2. The scoring balloon group in our study had less absolute reduction of -1.7 mm^2. Even though, we found a significant difference in MLA between the two groups, we still revealed lumen reduction in both groups from baseline to 6-month follow-up. Lumen reduction of 25% was considerably larger than the expected 11% lumen reduction anticipated in our power calculation.

The HONEST trial[25] comparing OCT- and angio-guided implantation with the MgBRS in a population with acute coronary syndrome found a significant reduction in MLA observed after 6 month in both groups with a relative difference of 33.2 % and 22.8 % in MLA, respectively. The mechanism behind lumen reduction may be due to additional post-dilatation in an attempt to optimize the apposition, resulting in fracture or dismantling of the scaffold hence reducing the radial strength[26]. Other mechanisms contributing to premature lumen loss after implantation of the MgBRS could be scaffold recoil, neointimal hyperplasia and impact of underlying plaque morphology and vessel remodeling[5]. The pattern of remodeling, with significant correlation between change in lumen area and change in vessel area, but not between change in lumen area and plaque area, indicated vessel reduction and not plaque increase as the overall reason for lumen reduction. The pattern of remodeling was similar in the two groups, but the overall magnitude of vessel reduction causing lumen reduction was larger in the standard non-compliant balloon group compared the scoring balloon group. Our results reported significantly more decrease in vessel area in lesions prepared with a standard non-compliant balloon, which was not seen in the lesions pre-dilated with the scoring balloon. This indicates that negative remodeling and vessel shrinkage may be contributing factors for lumen loss in our study in the standard non-compliant balloon group. In the ABSORB Cohort B trial, dynamics of the vessel wall was investigated with IVUS after implantation the everolimus-eluting bioresorbable ABSORB scaffold. They reported no evidence of late recoil, but enlargement of the vessel, lumen and scaffold area up to three years after implantation[27]. The early resorption of the MgBRS with fast loss of radial force has been suggested as a limiting factor to the device, and must be investigated further[5]. The extent of scaffold recoil is a balance between elastic recoil and radial strength and can be affected by the fibrotic plaque in the coronary artery in the treated segment[5]. Optimal pre-dilatation with a more aggressive lesion preparation could result in a better vascular healing and less lumen reduction[11]. More lipid-rich

plaques have been associated with less lumen loss after implantation of the MgBRS, whereas the constrictive vascular forces and rigidity of fibrotic plaque may facilitate lumen reduction[5]. Patients with acute coronary syndrome tend to have lesions with more lipid-rich plaque and positive remodeling compared to our population of patients with stabile coronary syndrome, which could explain more lumen reduction than expected in the current study.

Percentage of post-procedure malapposed struts was small in our study in both groups (1.46% for scoring balloon group and 4.57% for the standard non-compliant balloon group). As shown in previous trials[5, 19, 20, 22], most struts will not be visible after 6 months, due to the fast scaffold absorption. Even though we found up to 43% of the scaffolds with malapposition had follow-up, the percentage of malapposed struts and malapposition volume was low. Significantly less malapposition was present in the scoring balloon group compared to the standard non-compliant balloon group, which contributes to the assumption of better vascular healing after lesion preparation with a scoring balloon. To determine if these findings are a part of the natural healing process needs longer follow-up time.

Despite reported lumen loss after implantation of the MgBRS in various intravascular imaging studies[19, 22], the clinical performance is still deemed safe and efficient in several studies. Registries have reported safety and efficacy with low 1-year TLF rates of 3.3-5.4% and stent thrombosis rates of 0.5%, and TLF of 7.8% and scaffold thrombosis of 0.5% up to 24 months after implantation[9, 28, 29]. A registry study found no difference in 24-month clinical outcomes between patients with acute vs. stable coronary syndromes who were treated with a MgBRS[30]. Only few studies have compared the MgBRS to DES, for example the MAGSTEMI trial (MAGnesium-based bioresorbable scaffold in ST-segment Elevation Myocardial Infarction) that showed a significantly higher TLF rate in the MgBRS group after 1 year in a ST-segment elevation myocardial infarction population[10]. However, a retrospective cohort reported similar 1-year clinical outcome comparing the MgBRS to a

biodegradable polymer DES in a non-ST-segment elevation myocardial infarction cohort [31]. More randomized controlled trials with long-term follow-up are needed to fully illuminate the clinical benefits or disadvantages between the new generation BRS and traditional DES.

Limitations

There are some potential limitations to this study. The study was not powered to correlate clinical endpoints with OCT and IVUS findings. The study was conducted during the COVID-19 pandemic and was furthermore challenged by nurse strike and delivery problems of OCT catheters, why the inclusion period was unexpectedly prolonged. Also, the patient and lesion selections were influenced by limited available scaffold sizes.

Conclusion

After 6 months, lesion preparation with a scoring balloon, compared to a standard non-compliant balloon, prior to implantation of a MgBRS resulted in larger MLA, no remodeling and less malapposition, whereas negative remodeling was seen in the standard non-compliant balloon group.

Sources of funding

The study is an investigator-initiated trial, and did not receive any financial support.

Declaration of competing Interest

KNH, MN, JT, COF, MH, KTV, JEG, AJ, AM, JFL, HSH have no conflict of interests. LOJ has received research grants from Biotronik, OrbusNeich, Biosensors, and Terumo to her institution.

References

1. Azzi N, Shatila W. Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization. *Rev Cardiovasc Med*. 2021;22:137-145
2. Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. *Journal of the American College of Cardiology*. 2017;70:60-74
3. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: A systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. *Lancet (London, England)*. 2017;390:760-772
4. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. *Circulation*. 2010;122:2301-2312
5. Ueki Y, Räber L, Otsuka T, Rai H, Losdat S, Windecker S, et al. Mechanism of drug-eluting absorbable metal scaffold restenosis: A serial optical coherence tomography study. *Circulation. Cardiovascular interventions*. 2020;13:e008657
6. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (dreams) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man biosolve-i trial. *Lancet (London, England)*. 2013;381:836-844
7. Haude M, Ince H, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (dreams 2g) in patients with de novo coronary lesions: Three-year clinical results and angiographic findings of the biosolve-ii first-in-man trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2020;15:e1375-e1382
8. Haude M, Toelg R, Lemos PA, Christiansen EH, Abizaid A, von Birgelen C, et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the biosolve-ii first-in-man trial at 5 years. *Cardiovascular revascularization medicine : including molecular interventions*. 2022;38:106-110
9. Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, et al. Biosolve-iv-registry: Safety and performance of the magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2021;98:E1-e8
10. Sabaté M, Alfonso F, Cequier A, Romaní S, Bordes P, Serra A, et al. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with st-segment elevation myocardial infarction: The magstemi randomized clinical trial. *Circulation*. 2019;140:1904-1916
11. Miyazaki T, Latib A, Ruparelia N, Kawamoto H, Sato K, Figini F, et al. The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: A comparison with conventional balloon predilatation. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2016;11:e1580-1588
12. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the international working group for intravascular optical coherence tomography standardization and validation. *Journal of the American College of Cardiology*. 2012;59:1058-1072
13. Mintz GS, Guagliumi G. Intravascular imaging in coronary artery disease. *Lancet (London, England)*. 2017;390:793-809
14. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (ivus). A report of the american college of cardiology

task force on clinical expert consensus documents. *Journal of the American College of Cardiology*. 2001;37:1478-1492

15. Hansen KN, Maehara A, Noori M, Trøan J, Fallesen CO, Hougaard M, et al. Optimal lesion preparation before implantation of a magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the optimis study. *Contemp Clin Trials Commun*. 2024;38:101260
16. Gutiérrez-Chico JL, Cortés C, Schincariol M, Limon U, Yalcinli M, Durán-Cortés MA, et al. Implantation of bioresorbable scaffolds under guidance of optical coherence tomography: Feasibility and pilot clinical results of a systematic protocol. *Cardiology journal*. 2018;25:443-458
17. Maehara A, Matsumura M, Ali ZA, Mintz GS, Stone GW. Ivus-guided versus oct-guided coronary stent implantation: A critical appraisal. *JACC. Cardiovascular imaging*. 2017;10:1487-1503
18. Shlofmitz E, Croce K, Bezerra H, Sheth T, Chehab B, West NEJ, et al. The mld max oct algorithm: An imaging-based workflow for percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions*. 2022;100:S7-S13
19. Fallesen CO, Antonsen L, Maehara A, Noori M, Hougaard M, Hansen KN, et al. Optical coherence tomography- versus angiography-guided magnesium bioresorbable scaffold implantation in nstemi patients. *Cardiovascular revascularization medicine : including molecular interventions*. 2022;40:101-110
20. Waksman R, Prati F, Bruining N, Haude M, Böse D, Kitabata H, et al. Serial observation of drug-eluting absorbable metal scaffold: Multi-imaging modality assessment. *Circulation. Cardiovascular interventions*. 2013;6:644-653
21. Waksman R, Zumstein P, Pritsch M, Wittchow E, Haude M, Lapointe-Corriveau C, et al. Second-generation magnesium scaffold magmaris: Device design and preclinical evaluation in a porcine coronary artery model. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2017;13:440-449
22. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (biosolve-ii): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. *Lancet (London, England)*. 2016;387:31-39
23. Tovar Forero MN, van Zandvoort L, Masdjedi K, Diletti R, Wilschut J, de Jaegere PP, et al. Serial invasive imaging follow-up of the first clinical experience with the magmaris magnesium bioresorbable scaffold. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2020;95:226-231
24. Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, et al. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter biomag-i first-in-human study. *EClinicalMedicine*. 2023;59:101940
25. Fallesen CO, Maehara A, Antonsen L, Nørregaard Hansen K, Noori M, Flensted Lassen J, et al. Coronary artery healing process after bioresorbable scaffold in patients with non-st-segment elevation myocardial infarction: Rationale, design, and methodology of the honest study. *Cardiology*. 2021:1-11
26. Barkholt T, Webber B, Holm NR, Ormiston JA. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2020;96:E674-e682
27. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2014;9:1271-1284
28. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, et al. Sustained safety and efficacy of magnesium reabsorbable scaffold: 2-year follow-up analysis from first magmaris

multicenter italian registry. *Cardiovascular revascularization medicine : including molecular interventions*. 2022;41:69-75

29. Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, et al. Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of biosolve-ii and biosolve-iii. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2018;92:E502-e511
30. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, et al. Comparison of acute versus stable coronary syndrome in patients treated with the magmaris scaffold: Two-year results from the magmaris multicenter italian registry. *Cardiovascular revascularization medicine : including molecular interventions*. 2023;57:53-59
31. Rola P, Włodarczak A, Włodarczak S, Barycki M, Szudrowicz M, Łanocha M, et al. Magnesium bioresorbable scaffold (brs) magmaris vs biodegradable polymer des ultimaster in nste-acs population-12-month clinical outcome. *Journal of interventional cardiology*. 2022;2022:5223317

Table 1: Patient baseline characteristics

	Scoring balloon N = 41	**Standard balloon N = 41**
Age, years	64.9 ± 9.0	64.8 ± 7.9
Male, n (%)	27 (65.9)	28 (68.3)
Family history of IHD, n (%)	19 (46.3)	17 (41.5)
History of smoking, n (%)		
Current smoker	6 (14.6)	6 (14.6)
Previous smoker	21 (51.2)	11 (26.8)
Hypertension, n (%)	17 (41.5)	25 (61.0)
Hypercholesterolemia, n (%)	11 (26.8)	13 (31.7)
Diabetes mellitus, n (%)	4 (9.8)	8 (19.5)
Body mass index, kg/m^2	27.9 ± 9.7	27.9 ± 3.7
eGFR, ml/min	79.7 ± 12.5	82.1 ± 11.6
Previous myocardial infarction, n (%)	9 (22.0)	4 (9.8)
Previous PCI, n (%)	11 (26.8)	6 (14.6)
Previous CABG, n (%)	0 (0.0)	0 (0.0)

CABG = coronary bypass graft, eGFR = estimated glomerular filtration rate, IHD = ischemic heart disease, PCI = percutaneous coronary intervention. Data is shown as mean ± standard deviation.

Table 2: Procedural and angiographic characteristics

	Scoring balloon N = 41	Standard balloon N = 41
Target coronary artery, n (%)		
Left anterior descending	23 (56.1)	24 (58.5)
Left circumflex	6 (14.6)	8 (19.5)
Right coronary artery	12 (29.3)	9 (22.0)
Lesion length, mm	23.9 ± 10.5	22.5 ± 5.4
Reference vessel diameter, mm	3.4 ± 0.3	3.4 ± 0.3
Pre-dilatation, n (%)	41 (100)	41 (100)
Balloon diameter at pre-dilatation, mm	3.3 ± 0.3	3.3 ± 0.3
Balloon length at pre-dilatation, mm	13.1 ± 2.5*	15.5 ± 3.3
Max balloon pressure at pre-dilatation, atm	13.1 ± 2.8	14.0 ± 2.7
Number of scaffolds per lesion, mm	1.1 ± 0.3	1.1 ± 0.2
Scaffold length, mm	19.4 ± 4.1	21.0 ± 3.9
Scaffold diameter, mm	3.3 ± 0.2	3.3 ± 0.3
Maximum balloon pressure, atm	11.9 ± 2.2	12.0 ± 2.4
Expected scaffold diameter, mm	3.4 ± 0.3	3.4 ± 0.3
Post-dilatation, n (%)	38 (93)	41 (100)
Balloon diameter at post-dilatation, mm	3.7 ± 0.3	3.7 ± 0.4
Balloon length at post-dilatation, mm	14.5 ± 3.6	15.7 ± 3.3
Max balloon pressure at post-dilatation, atm	13.0 ± 2.6	12.8 ± 2.4
Flouro time, minutes	12.3 ± 5.3	11.8 ± 5.2

Contrast volume, ml	108.0 ± 42.9	102.6 ± 43.8
Procedure time, minutes	49.9 ± 17.7	47.9 ± 18.4
* significantly shorter balloon length at pre-dilatation in the scoring balloon group (p-value < 0.001)		

Table 3: Post-procedure and 6-month follow-up optical coherence tomography findings and intravascular ultrasound						
	Baseline			6-month follow-up		
	Scoring balloon	Standard balloon	p-value	Scoring balloon	Standard balloon	p-value
OCT finding						
Number of patients	40	38		39	35	
Time to 6-month follow-up, days				185 [182 ; 234]	184 [182 ; 192]	0.29
Lumen measurement						
Minimal lumen area, mm^2	6.42 ± 1.55	6.27 ± 1.48	0.65	4.71 ± 1.35	3.91 ± 1.86	0.04
Difference in minimal lumen area (6 months - baseline), mm^2				-1.70 ± 1.49	-2.30 ± 1.42	0.08
Relative change in minimal lumen area (6 months - baseline), %				-24.8 ± 20.4	-38.3 ± 22.7	0.009
Mean lumen area, mm^2	8.01 ± 1.62	7.66 ± 2.12	0.41	7.21 ± 1.41	6.79 ± 2.21	0.35
Total lumen volume, mm^3	167.31 ± 50.82	169.47 ± 54.70	0.86	151.50 ± 53.94	139.93 ± 52.95	0.36
Difference in total lumen volume (6 months - baseline), mm^3				-16.99 ± 21.35	-25.35 ± 28.45	0.16
Relative change in total lumen volume (6 months - baseline), %				-10.5 ± 11.7	-15.0 ± 16.8	0.20

Scaffold measurement						
Total number of analyzable struts	199.9 ± 70.5	210.7 ± 60.0	0.46	70.8 ± 35.1	85.1 ± 32.1	0.07
Mean no. of struts per cross section	9.11 ± 0.71	9.11 ± 0.82	1.00	3.1 ± 1.3	3.9 ± 1.7	0.03
Scaffold length, mm	20.8 [16.5 ; 24.1]	22.2 [19.2 ; 24.8]	0.51	20.4 [17.2 ; 24.0]	21.0 [17.2 ; 25.2]	0.69
Minimal scaffold area, mm^2	6.40 ± 1.50	6.09 ± 1.51	0.36			
Mean scaffold area, mm^2	7.77 ± 1.49	7.45 ± 1.69	0.37			
Total scaffold volume, mm^3	161.81 ± 45.93	160.88 ± 52.44	0.93			
Scaffold malapposition						
Scaffold malapposition, n (%)	20 (50.0)	21 (55.3)	0.64	6 (15.4)	15 (42.9)	0.009
Total malapposition volume, mm^3	0.38 [0.15 ; 0.95]	1.07 [0.48 ; 2.27]	0.09	0.0 [0.0 ; 0.0]	0.21 [0.0 ; 0.59]	0.009
Mean malapposition distance, mm	0.23 [0.21 ; 0.28]	0.30 [0.25 ; 0.34]	0.003	0.0 [0.0 ; 0.0]	0.18 [0.0 ; 0.4]	0.004
Percentage of malapposed struts, %	1.5 [0.6 ; 3.0]	4.57 [1.7 ; 5.8]	0.02	0.0 [0.0 ; 0.0]	1.6 [0.0 ; 3.5]	0.004
Types of incomplete stent apposition						
Resolved, n (%)				17 (48.6)	11 (31.4)	0.28
Persistent, n (%)				2 (5.0)	7 (20.0)	0.05
Late acquired, n (%)				4 (10.3)	8 (22.9)	0.14

Intravascular ultrasound						
Number of patients	40	38		39	34	
Time to 6-month follow-up, days				183 [153 ; 290]	183.5 [134 ; 225]	0.66
Vessel measurements						
EEM area at MLA site, mm^2	14.73 ± 3.39	16.19 ± 4.87	0.13	13.53 ± 3.50	13.70 ± 4.69	0.86
Mean EEM area, mm^2	16.70 ± 2.87	16.96 ± 4.22	0.75	16.24 ± 3.23	15.59 ± 4.66	0.50
Total EEM volume, mm^3	361.61 ± 97.49	383.88 ± 130.23	0.40	353.91 ± 120.67	336.85 ± 110.95	0.53

563

564

Table 4: Remodeling of lesion segment pre-procedure and corresponding segment post-procedure and at 6-month follow-up assessed with IVUS

	Scoring N = 39	Standard N = 34	p-value
Mean lumen (mm^2)			
Pre-procedure	5.3 ± 1.4	4.8 ± 1.5	0.13
Post-procedure	8.5 ± 1.4	8.2 ± 1.7	0.31
6-month follow-up	8.1 ± 1.8	7.4 ± 2.6	0.19
Change (6 months – baseline)	-0.4 ± 1.5	-0.8 ± 1.6	0.41
p-value (baseline vs. 6 months)*	0.08	0.009	
Mean EEM area (mm^2)			
Pre-procedure	13.3 ± 3.1	13.4 ± 4.8	0.88
Post-procedure	16.8 ± 2.9	17.1 ± 4.4	0.74
6-month follow-up	17.0 ± 3.6	15.7 ± 4.9	0.20
Change (6 months – baseline)	0.2 ± 2.0	-1.4 ± 2.0	0.001
p-value (baseline vs. 6 months)*	0.62	< 0.001	
Mean plaque area (mm^2)			
Pre-procedure	7.9 ± 2.5	8.6 ± 3.9	0.39
Post-procedure	8.3 ± 2.0	8.9 ± 3.5	0.31
6-month follow-up	8.9 ± 2.4	8.3 ± 3.0	0.36
Change (6 months – baseline)	0.6 ± 1.3	-0.7 ± 1.9	0.002
p-value (baseline vs. 6 months)*	0.007	0.06	
Mean scaffold area (mm^2)			

	Post-procedure	9.5 ± 1.7	9.1 ± 1.9	0.26
	6-month follow-up	10.1 ± 2.1	8.9 ± 2.8	0.04
	Change (6 months – baseline)	0.6 ± 1.9	-0.2 ± 1.8	0.10
	p-value (baseline vs. 6 months)*	0.07	0.58	
*paired analysis				

Figures and legends

Figure 1: Flow chart



Figure 2: Intravascular images of lumen reduction after implantation of Magmaris bioresorbable scaffold.



The upper panel shows OCT images of minimal lumen area from baseline and the corresponding site at follow-up. The lower panel shows the matching site acquired with IVUS. Images A and B represent the vascular healing after lesion preparation with a scoring balloon prior to MgBRS implantation. Lumen area at baseline was 7.3 mm^2 measured with OCT and 7.5 mm^2 with IVUS. Vessel area was 12.7 mm^2 at

baseline (A). At 6-month follow-up, lumen area was 8.8 mm^2 with OCT and 8.8 mm^2 with IVUS. Vessel area was 16.0 mm^2 (B). Images C and D represent the vascular healing after implantation of a MgBRS in a lesion pre-dilated with a standard non-compliant balloon. Lumen area at baseline was 8.8 mm^2 with OCT and 8.8 mm^2 with IVUS. Vessel area was 16.0 mm^2 (C). After 6 months, the matching site was reduced to 5.1 mm^2 measured with OCT, and 5.6 mm^2 with IVUS. Vessel area was 13.8 mm^2 (D). Abbreviations: IVUS = Intravascular ultrasound; MgBRS = Magmaris bioresorbable scaffold; OCT = Optical coherence tomography.

579 Figure 3: Optical coherence tomography images of malapposition types



580

581 Upper panel represents baseline optical coherence tomography images, and lower panel represents
582 6-month follow-up. A) There are three malapposed struts from 3 to 5 o'clock, and one malapposed
583 strut at 10 o'clock. The corresponding site after 6 months (B) revealed resolved malapposition from
584 3 to 5 o'clock, but persistent malapposition at 10 o'clock. C) Four malapposed struts are visible at
585 baseline from 5 to 7 o'clock. At 6-month follow-up, persistent malapposition is seen in the
586 corresponding cross section (D). E) All struts are well-apposed, but after 6 month acquired
587 malapposition appears at 7 to 8 o'clock.

Figure 4: Pattern of remodeling at the lesion site



A. Correlation between relative change in lumen area (%) and relative change in vessel area (%) at the lesion site. B. Correlation between relative change in lumen area (%) and relative change in plaque area at the lesion site


Screening
15 dec 2020 – 8 sep 2023
Inclusion
Included in OPTIMIS study
N = 82
Randomization 1:1
Peri-procedural exclusion
Device failure, n = 1
Procedure failure, n = 0
Allocated to pre-dilatation with a scoring ballon
N = 41
Allocated to pre-dilatation with a standard ballon
N = 41
Peri-procedural exclusion
Device failure, n = 1
Procedure failure, n = 1
Baseline
Baseline OCT available (n=40)
Baseline IVUS available (n=41)
Baseline OCT available (n=39)
Baseline IVUS available (n=41)
Lost to invasive follow-up
Withdrawn consent, n = 1
Death, n = 0
Scaffold thrombosis, n = 0
6-month OCT/IVUS follow-up
Lost to invasive follow-up
Withdrawn consent, n = 1
Death, n = 1
Scaffold thrombosis, n = 1
Postponed (nurses strike), n = 1
(Technical failure IVUS, n=1)
6-month OCT available (n=39)
6-month IVUS available (n=39)
6-month OCT available (n=35)
6-month IVUS available (n=34)


A
B
C
D
1 mm


A
C
E
B
D
F


A
Relative change in lumen area (%)
20
0
-20
-40
-30
-20
-10
0
10
20
Relative change in vessel area (%)
r = 0.72 (95%CI 0.58-0.81)
p < 0.001
Scoring
Standard
Fitted


B
Relative change in lumen area (%)
20
0
-20
-40
-40
-20
0
20
40
Relative change in plaque area (%)
r = - 0.02 (95%CI -0.25-0.21)
p = 0.88
Scoring
Standard
Fitted